Jain Aklank, Rajeswari Moganty R
Department of Biochemistry, All India Institute of Medical Science, New Delhi 110029, India.
J Biomol Struct Dyn. 2002 Oct;20(2):291-9. doi: 10.1080/07391102.2002.10506844.
The binding of quinolones, nalidixic acid (Nal), oxolinic acid (Oxo) with double stranded polynucleotides was undertaken by using UV-melting, UV-Vis absorption, fluorescence and CD spectroscopic techniques. The binding of Nal or Oxo to the polynucleotides under low-salt buffer conditions were determined for poly (dA).(dT), poly [d(A-T)], poly (dG).(dC), poly [d(G-C)] and E. coli DNA. The fluorescence data were analyzed using a previously established two step mechanism with two different DNA-Drug complexes [Rajeswari et al., Biochemistry 26, 6825-31 (1987)]. The first complex DN with a binding constant K(1), is formed where the interactions are 'nonspecific' and complex DN with a binding constant K(2), is formed where the interactions are "specific" which involve (additional) hydrophobic type of interactions like 'stacking' of the drug and the overall association constant is represented as K(=K(1)K(2)). The order of binding for Nal and Oxo is: poly [d(G-C)] > poly [d(A- T)] > E. coli > poly (dG).(dC) > poly (dA).(dT). Interaction of quinolones seems to be preferential in the alternating G, C or A, T stretches of DNA than those of non-alternating. Within any alternating or non-alternating in DNA sequences the G, C rich sequences have distinctly greater binding than A, T sequences. The overall association constant data (K) reveal higher binding of Oxo to DNA compared to Nal to any given polynucleotide investigated; which also explains the higher antibacterial potency of Oxo. Changes in the absorption difference spectra and in circular dichroic spectra also manifest these results. As the melting temperatures of the polynucleotides were only marginally raised in presence of the quinolone, we rule out the possibility of 'classical intercalation' of the drug. Amino group of guanine facilitates the binding of quinolones and therefore has the greater binding with the DNA. However, poly (dG).(dC) is known to exist in 'A' conformation which is not adopted by quinolones as in the case of poly (dA).(dT). Present results suggest that Nal or Oxo bind to DNA in a non-classical fashion which is partially stacking in nature.
利用紫外熔解、紫外可见吸收、荧光和圆二色光谱技术研究了喹诺酮类药物萘啶酸(Nal)、恶喹酸(Oxo)与双链多核苷酸的结合情况。在低盐缓冲条件下,测定了Nal或Oxo与聚(dA)·(dT)、聚[d(A - T)]、聚(dG)·(dC)、聚[d(G - C)]和大肠杆菌DNA的结合情况。荧光数据采用先前建立的两步机制进行分析,该机制涉及两种不同的DNA - 药物复合物[Rajeswari等人,《生物化学》26,6825 - 31(1987)]。首先形成具有结合常数K(1)的复合物DN,其相互作用为“非特异性”;然后形成具有结合常数K(2)的复合物DN,其相互作用为“特异性”,涉及药物的(额外)疏水相互作用类型,如药物的“堆积”,总缔合常数表示为K(=K(1)K(2))。Nal和Oxo的结合顺序为:聚[d(G - C)] > 聚[d(A - T)] > 大肠杆菌 > 聚(dG)·(dC) > 聚(dA)·(dT)。喹诺酮类药物似乎优先与DNA中交替的G、C或A、T序列结合,而非交替序列。在DNA序列的任何交替或非交替区域内,富含G、C的序列比富含A、T的序列具有明显更强的结合能力。总缔合常数数据(K)表明,与Nal相比,Oxo与任何给定的研究多核苷酸结合能力更强;这也解释了Oxo更高的抗菌效力。吸收差光谱和圆二色光谱的变化也证实了这些结果。由于在喹诺酮存在下多核苷酸的熔解温度仅略有升高,我们排除了药物“经典嵌入”的可能性。鸟嘌呤的氨基促进了喹诺酮类药物的结合,因此与DNA的结合更强。然而,已知聚(dG)·(dC)以“A”构象存在,而喹诺酮类药物不像聚(dA)·(dT)那样采用这种构象。目前的结果表明,Nal或Oxo以非经典方式与DNA结合,这种方式在本质上部分是堆积作用。